Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
2024 · The Oncologist · 32 citations
https://doi.org/10.1093/oncolo/oyae055
Q
Qixiang Rong
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
18
Papers
219
Citations
8
h-index
7
i10-index
Qixiang Rong is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 8, co-authored 16 publications.
ORCID: 0000-0001-7719-4243Papers by this author
worksImpacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
2025 · Journal of Translational Medicine · 5 citations
https://doi.org/10.1186/s12967-025-06082-5
Additional file 1 of GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14702349
Additional file 2 of GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14702352
Additional file 4 of GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14702358
Additional file 3 of GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14702355
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat